瑞士BioVersys公司在新的结核病治疗抗药性方面获得EMA孤儿药物地位。 Swiss firm BioVersys gets EMA orphan drug status for new TB treatment combating resistance.

瑞士BioVersys公司已经从EMA获得孤儿的称号,以进行一种将白化病人和乙酰胺结合的新型结核病治疗。 Swiss company BioVersys has received orphan designation from the EMA for a new tuberculosis treatment combining alpibectir and ethionamide. 这种新颖的结合旨在克服肺结核药物的抗药性,这是一个重要的全球健康问题。 This novel combination aims to overcome drug resistance in TB, a major global health issue. 在几个欧洲赠款的支持下,治疗在防治肺部和脑膜炎结核病方面显示出潜力,为改进治疗选择提供了希望。 Supported by several European grants, the treatment shows potential in fighting both pulmonary and meningeal TB, offering hope for improved treatment options.